Coronavirus

Public understanding of adverse events could be an obstacle in the rollout of vaccines to fight the coronavirus disease 2019 (COVID-19).

An overall COVID-19 mortality rate of more than 5% for those admitted to a hospital highlights the urgent need for treatments.

A large-scale diagnosis of SARS-CoV-2 is paramount to downregulating its spread and mitigating the current outbreak.

The primary outcome was to determine how many cases of symptomatic COVID-19 disease there were in participants who had received two doses of the vaccine.

The updated vaccine efficacy and safety outcomes include 37,000-plus participants from the ongoing, multi-national trial.

In the middle of the worst surge the United States has seen as of yet, with over 200000 new cases a day and over 100000 people hospitalized, how do New Yorkers feel about the pandemic?

The need for rapid, widespread, accurate testing has motivated research exploring new potential strategies.

Investigators identify gene expression which may explain the highly transmissible nature of the virus.

The study was posted to the website clinicaltrials.gov this past Wednesday.

Authorization for a COVID-19 vaccine in the US appears imminent, bringing with it a host of concerns including the speed of development, inclusivity of clinical trials, safety of mRNA technology, and how to raise levels of trust in vulnerable populations.

WHO has recently recommended using assessment for monitoring of clinical deterioration in patients with COVID-19.

Previous studies with influenza in animals demonstrated antiviral efficacy was not species restricted.

Tonix Pharmaceuticals is developing a horsepox virus vector vaccine based on a historic platform which was first used for smallpox, and applying it to the world’s most recent virus.

Physicians are beginning to find key patterns which will aid public health in the future.

While the antibodies declined slightly at 3 months, all participants showed elevated levels.

Further investigation has to be conducted before this method can be used in human patients.

Group is first to demonstrate the activation of inflammasome in response to infection by SARS-CoV-2.

COVID-19 is a dynamic disease which evolves as it disrupts host programs and rewires modules.

The agency adds 2 options lowering the number of days to isolate.

The research has helped almost 100 patients so far at the Royal Albert Edward Infirmary.

The Advisory Committee on Immunization Practices (ACIP) met yesterday and decided that healthcare workers and residents in long-term care facilities will be prioritized as the first people eligible for the impending COVID-19 vaccines.

Can chemical compounds found in certain foods aid in the fight against COVID-19?

LabCorp, an early adopter with extensive geographic reach, will be the first lab offering the test in the United States.

The companies are ready to ship doses immediately.

Mady Hornig, MA, MD, discusses the mental and emotional aspects of dealing with a diagnosis and the evolution of how people are processing the virus many months later after it started.

A team at Columbia University's Mailman School of Public Health is partnering with a chronic fatigue syndrome (CFS) organization to study COVID-19 and CFS.

Recent study may have implications for social and public health policies

Olfactory dysfunction is a critical loss of information that is important for responding to our environment.

Researchers produce the first-ever electron microscopy images of intact coronavirus particles within olfactory mucosa.

A team at Columbia University's Mailman School of Public Health is looking at the long term of effects in some patients who are suffering from this phenomenon.